Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (834)	11/26/2001 8:23:42 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

KvE is again over his head! Where did he found that LLY is NBIX malanocortin partner? It was Urocortin, but not Malanocortin! Message 16705484 <<Neurocrine Biosciences is also searching for a reliable obesity treatment. The firm's most promising remedy is Melanocortin Agonist, which targets the melanocortin receptors of the brain. They are involved in the body's endocrine, autonomic, and central nervous systems and regulate appetite, body weight, and insulin secretion. This compound may also be of value for treating anorexia nervosa and diabetes. Eli Lilly is the firm's partner in the project. >. Or maybe he knows something that we do not??? Miljenko